Tango Therapeutics announced on June 8 that its experimental PRMT5 inhibitor, when combined with Revolution Medicines’ RAS inhibitor, achieved a 92% response rate in pancreatic cancer patients. This result surpassed the responses seen from either therapy alone or in combination with chemotherapy.
Leerink Partners commented on the results, stating, “WOW!” and forecasted that Tango’s stock could at least double based on the data. Following the announcement, Tango’s share price increased by 43% to $28.94 as markets opened Monday. Revolution Medicines’ stock also saw a slight increase of just under 1%, reaching $150.62.
“The results from our ongoing combination trial dramatically exceeded our expectations,” said Malte Peters, CEO of Tango Therapeutics, during an investor call. Peters said that given these results, the company is planning registrational trials for this combination strategy as a front-line treatment.
The data come from an ongoing Phase 1/2 study evaluating Tango’s vopimetostat with either Revolution Medicines’ zoldonrasib or daraxonrasib in patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC). Earlier this year, daraxonrasib alone doubled survival to 13.2 months in PDAC compared to chemotherapy—a notable improvement for a disease where five-year survival is about 13%. In this new dose-escalation arm involving daily administration of vopimetostat and daraxonrasib among twelve PDAC patients followed for fourteen weeks, eleven showed objective responses—nine of which were confirmed—resulting in a reported objective response rate of 92%. The study also reported a disease control rate of 100% for these twelve patients and a six-month progression-free survival rate of 90%.
Leerink Partners analysts wrote, “The efficacy results speak for themselves,” describing “unprecedented activity” and suggesting strong synergy between the two agents regarding both response rates and durability. Among three evaluable NSCLC patients at fourteen weeks follow-up, all achieved an objective response; however, Leerink noted these data are too limited to predict long-term outcomes.
Regarding safety, Tango said no new safety signals were observed with the investigational combination approach; no patient discontinued due to adverse events nor experienced grade four or five events. The company indicated plans to advance into Phase 3 development for first-line MTAP-deleted pancreatic cancer pending regulatory feedback.
